Drug Patents Expiring in 2028

1. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119554 OTSUKA Pharma-informatics system Dec, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ACUVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192571 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Mar, 2028

(5 years from now)

US8512717 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same Mar, 2028

(5 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.45% SOLUTION/DROPS;OPHTHALMIC Prescription

3. Drug name - AFINITOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006224 NOVARTIS Neuroendocrine tumor treatment Jul, 2028

(5 years from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

4. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8651103 TEVA PHARM Dry powder inhalation apparatus Mar, 2028

(5 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus Sep, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

5. Drug name - ALVESCO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases Feb, 2028

(5 years from now)

Drugs and Companies using CICLESONIDE ingredient

Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.08MG/INH AEROSOL, METERED;INHALATION Prescription
0.16MG/INH AEROSOL, METERED;INHALATION Prescription

6. Drug name - ANGIOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7598343 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same Jul, 2028

(5 years from now)

US7582727 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same Jul, 2028

(5 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL INJECTABLE;INTRAVENOUS Prescription

7. Drug name - ANORO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXOSMITHKLINE Medicament dispenser Feb, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

8. Drug name - APTIOM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763954 SUNOVION PHARMS INC Therapeutical uses of eslicarbazepine Sep, 2028

(5 years from now)

US10912781 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Oct, 2028

(6 years from now)

US9566244 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Oct, 2028

(6 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Treatment: Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

9. Drug name - ARCAPTA NEOHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device Oct, 2028

(6 years from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 75MCG BASE POWDER;INHALATION Discontinued

10. Drug name - ARIKAYCE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226975 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Aug, 2028

(5 years from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: NA

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription

11. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8651103 TEVA PHARM Dry powder inhalation apparatus Mar, 2028

(5 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus Sep, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

12. Drug name - ARNUITY ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXOSMITHKLINE Medicament dispenser Feb, 2028

(5 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.05MG/INH POWDER;INHALATION Prescription
0.1MG/INH POWDER;INHALATION Prescription
0.2MG/INH POWDER;INHALATION Prescription

13. Drug name - ASTEPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071073 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof Jun, 2028

(5 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY SPRAY, METERED;NASAL Discontinued
0.2055MG/SPRAY SPRAY, METERED;NASAL Discontinued

14. Drug name - ASTEPRO ALLERGY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof Jun, 2028

(5 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.2055MG/SPRAY SPRAY, METERED;NASAL Over the counter

15. Drug name - ATELVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7645460 APIL Dosage forms of risedronate Jan, 2028

(5 years from now)

US7645459 APIL Dosage forms of bisphosphonates Jan, 2028

(5 years from now)

Drugs and Companies using RISEDRONATE SODIUM ingredient

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
35MG TABLET, DELAYED RELEASE;ORAL Prescription

16. Drug name - AUVI-Q

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947017 KALEO INC Devices, systems and methods for medicament delivery Mar, 2028

(5 years from now)

US7749194 KALEO INC Devices, systems, and methods for medicament delivery Oct, 2028

(6 years from now)

US8231573 KALEO INC Medicament delivery device having an electronic circuit system Nov, 2028

(6 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.15MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.3MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription

17. Drug name - BEVYXXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557852 PORTOLA PHARMS INC Methods of using crystalline forms of a salt of a factor Xa inhibitor Sep, 2028

(5 years from now)

Drugs and Companies using BETRIXABAN ingredient

Treatment: Prophylaxis of deep vein thrombosis (dvt); prophylaxis of venous thrombosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Discontinued
80MG CAPSULE;ORAL Discontinued

18. Drug name - BREO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXO GRP LTD Medicament dispenser Feb, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

19. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8216180 ASTRAZENECA AB Administering apparatus with functional drive element Jan, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps Mar, 2028

(5 years from now)

US9320853 ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule Mar, 2028

(5 years from now)

US8758292

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element May, 2028

(5 years from now)

US8216180

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element Jul, 2028

(5 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Sep, 2028

(5 years from now)

US9320853

(Pediatric)

ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule Sep, 2028

(5 years from now)

US8439864

(Pediatric)

ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps Sep, 2028

(5 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

20. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Sep, 2028

(5 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

21. Drug name - CANASA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8436051 ALLERGAN Mesalamine suppository Jun, 2028

(5 years from now)

US8217083 ALLERGAN Mesalamine suppository Jun, 2028

(5 years from now)

Drugs and Companies using MESALAMINE ingredient

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

More Information on Dosage
Strength Dosage Availability
1GM SUPPOSITORY;RECTAL Prescription
500MG SUPPOSITORY;RECTAL Discontinued

22. Drug name - CAPLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 42MG BASE CAPSULE;ORAL Prescription

23. Drug name - CAPRELSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474 Aug, 2028

(5 years from now)

Drugs and Companies using VANDETANIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

24. Drug name - CARNEXIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629797 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation Nov, 2028

(6 years from now)

US9770407 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation Nov, 2028

(6 years from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or generalized seizures

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/20ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

25. Drug name - COLCRYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7981938 TAKEDA PHARMS USA Colchicine compositions and methods Oct, 2028

(6 years from now)

US7964648 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Oct, 2028

(6 years from now)

US8415396 TAKEDA PHARMS USA Colchine compositions and methods Oct, 2028

(6 years from now)

US8093297 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Oct, 2028

(6 years from now)

US8415395 TAKEDA PHARMS USA Colchicine compositions and methods Oct, 2028

(6 years from now)

US8093298 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Oct, 2028

(6 years from now)

US8097655 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Oct, 2028

(6 years from now)

US7964647 TAKEDA PHARMS USA Colchicine compositions and methods Oct, 2028

(6 years from now)

US8093296 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Oct, 2028

(6 years from now)

US7619004 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Dec, 2028

(6 years from now)

US7935731 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Dec, 2028

(6 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: A method for treatment of gout flares during prophylaxis; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; Method of treating gout flares; Method of administering colchicine to familial mediterranean fever patients; Method of using colchicine for the prophylaxis of gout flares

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.6MG TABLET;ORAL Prescription

26. Drug name - COMBIVENT RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED;INHALATION Prescription

27. Drug name - CUBICIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage Sep, 2028

(5 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL POWDER;INTRAVENOUS Discontinued
500MG/VIAL POWDER;INTRAVENOUS Prescription

28. Drug name - DAURISMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

29. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871273 TAKEDA PHARMS USA Method for producing granules Jan, 2028

(5 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

30. Drug name - DEXILANT SOLUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871273 TAKEDA PHARMS USA Method for producing granules Jan, 2028

(5 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules Jul, 2028

(5 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

31. Drug name - DIFFERIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7998467 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers May, 2028

(5 years from now)

Drugs and Companies using ADAPALENE ingredient

Treatment: Treatment of acne

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1% LOTION;TOPICAL Prescription

32. Drug name - DIFICID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jan, 2028

(5 years from now)

US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jan, 2028

(5 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B Jan, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

33. Drug name - DORAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7608616 GALT PHARMS Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia Jun, 2028

(5 years from now)

Drugs and Companies using QUAZEPAM ingredient

Treatment: Method for treating insomnia while reducing the risk of an adverse drug interaction

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
7.5MG TABLET;ORAL Discontinued
15MG TABLET;ORAL Prescription

34. Drug name - DORYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8715724 MAYNE PHARMA Tabletting process Feb, 2028

(5 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 80MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 60MG BASE TABLET, DELAYED RELEASE;ORAL Discontinued
EQ 120MG BASE TABLET, DELAYED RELEASE;ORAL Prescription

35. Drug name - DUETACT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071130 TAKEDA PHARMS USA Solid preparation Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
2MG;30MG TABLET;ORAL Prescription
4MG;30MG TABLET;ORAL Prescription

36. Drug name - DUZALLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use Nov, 2028

(6 years from now)

US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use Nov, 2028

(6 years from now)

US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use Nov, 2028

(6 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG;200MG TABLET;ORAL Discontinued
300MG;200MG TABLET;ORAL Discontinued

37. Drug name - EDARBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066936 ARBOR PHARMS LLC Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL TABLET;ORAL Prescription
EQ 80MG MEDOXOMIL TABLET;ORAL Prescription

38. Drug name - EDARBYCLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066936 ARBOR PHARMS LLC Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL;12.5MG TABLET;ORAL Prescription
EQ 40MG MEDOXOMIL;25MG TABLET;ORAL Prescription

39. Drug name - ELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844510 LAB HRA PHARMA Ulipristal acetate tablets Dec, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription

40. Drug name - ENVARSUS XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549918 VELOXIS PHARMS INC Stabilized tacrolimus composition May, 2028

(5 years from now)

US11123331 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients May, 2028

(5 years from now)

US10166190 VELOXIS PHARMS INC Stabilized tacrolimus composition May, 2028

(5 years from now)

US10864199 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients May, 2028

(5 years from now)

US11110081 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients May, 2028

(5 years from now)

US8685998 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients Aug, 2028

(5 years from now)

US8664239 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients Aug, 2028

(5 years from now)

Drugs and Companies using TACROLIMUS ingredient

Treatment: Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient; Prophylaxis of organ rejection; prophylaxis of organ rejection in de novo transplant patient; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.75MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

41. Drug name - EPCLUSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

EP2826784A1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2826784B1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA Mar, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
150MG;37.5MG/PACKET PELLETS;ORAL Prescription
200MG;50MG/PACKET PELLETS;ORAL Prescription

42. Drug name - ERIVEDGE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7888364 GENENTECH Pyridyl inhibitors of hedgehog signalling
Nov, 2028

(6 years from now)

EP1789390A2 GENENTECH Pyridyl Inhibitors Of Hedgehog Signalling
Jul, 2028

(5 years from now)

EP1789390B1 GENENTECH Pyridyl Inhibitors Of Hedgehog Signalling
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278961 GENENTECH Pyridyl inhibitors of hedgehog signalling Dec, 2028

(6 years from now)

Drugs and Companies using VISMODEGIB ingredient

Treatment: Method of using vismodegib to treat cancer in a mammal

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG CAPSULE;ORAL Prescription

43. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947017 KALEO INC Devices, systems and methods for medicament delivery Mar, 2028

(5 years from now)

US7749194 KALEO INC Devices, systems, and methods for medicament delivery Oct, 2028

(6 years from now)

US8231573 KALEO INC Medicament delivery device having an electronic circuit system Nov, 2028

(6 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

44. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947017 KALEO INC Devices, systems and methods for medicament delivery Mar, 2028

(5 years from now)

US7749194 KALEO INC Devices, systems, and methods for medicament delivery Oct, 2028

(6 years from now)

US8231573 KALEO INC Medicament delivery device having an electronic circuit system Nov, 2028

(6 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

45. Drug name - EXONDYS 51

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9243245 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders
Oct, 2028

(6 years from now)

CN102264903A SAREPTA THERAPS INC Method And Means For Effectively Jumping Front Mrna Exon 45 Of Human Duchenne
Oct, 2028

(6 years from now)

CN102264903B SAREPTA THERAPS INC Method And Means For Effectively Jumping Front Mrna Exon 45 Of Human Duchenne
Oct, 2028

(6 years from now)

CN105641700B SAREPTA THERAPS INC Methods And Methods For Combating Muscular Disorders
Oct, 2028

(6 years from now)

CN105641700A SAREPTA THERAPS INC A Muscular Disorder-Resisting Mode And Method
Oct, 2028

(6 years from now)

EP2614827A2 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2203173B1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2203173A2 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2614827A3 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP3238737A1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2614827B1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP3238737B1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48468 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders Oct, 2028

(6 years from now)

Drugs and Companies using ETEPLIRSEN ingredient

Treatment: Treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription
500MG/10ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

46. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Aug, 2028

(5 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

47. Drug name - FARYDAK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7989494 SECURA Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Jan, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883842 SECURA Use of HDAC inhibitors for the treatment of myeloma Jun, 2028

(5 years from now)

Drugs and Companies using PANOBINOSTAT LACTATE ingredient

Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE CAPSULE;ORAL Discontinued
EQ 15MG BASE CAPSULE;ORAL Discontinued
EQ 20MG BASE CAPSULE;ORAL Discontinued

48. Drug name - FENTORA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7862833 CEPHALON Effervescent oral opiate dosage forms and methods of administering opiates Jun, 2028

(5 years from now)

US7862832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering Jun, 2028

(5 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.2MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.3MG BASE TABLET;BUCCAL, SUBLINGUAL Discontinued
EQ 0.4MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.6MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.8MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription

49. Drug name - FLO-PRED

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799331 TARO Oral suspension of prednisolone acetate Oct, 2028

(6 years from now)

Drugs and Companies using PREDNISOLONE ACETATE ingredient

Treatment: Treatment of asthma; treatment of allergic reactions

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE/5ML SUSPENSION;ORAL Discontinued
EQ 15MG BASE/5ML SUSPENSION;ORAL Discontinued

50. Drug name - FLONASE SENSIMIST ALLERGY RELIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8347879 GLAXOSMITHKLINE CONS Fluid dispensing device Jul, 2028

(5 years from now)

US8147461 GLAXOSMITHKLINE CONS Fluid dispensing device Oct, 2028

(6 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.0275MG/SPRAY SPRAY, METERED;NASAL Over the counter

51. Drug name - GALAFOLD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525045 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

US10925866 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

US11033538 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

US9999618 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients; A method of reducing podocyte globotriaosylceramide (gl-3) in a fabry patient by administering migalastat; a method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 123MG BASE CAPSULE;ORAL Prescription

52. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

53. Drug name - GLYXAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

54. Drug name - GOCOVRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8389578 ADAMAS PHARMA Composition and method for treating neurological disease Jan, 2028

(5 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 68.5MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 137MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

55. Drug name - HARVONI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

EP2826784A1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2826784B1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA Mar, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
33.75MG;150MG/PACKET PELLETS;ORAL Prescription
45MG;200MG/PACKET PELLETS;ORAL Prescription

56. Drug name - HEMANGEOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338489 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas Oct, 2028

(6 years from now)

US8987262 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas Oct, 2028

(6 years from now)

Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient

Treatment: Method to treat hemangioma.; Method to treat infantile hemangioma

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
4.28MG/ML SOLUTION;ORAL Prescription

57. Drug name - INCIVEK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615 VERTEX PHARMS Dose forms May, 2028

(5 years from now)

Drugs and Companies using TELAPREVIR ingredient

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
375MG TABLET;ORAL Discontinued

58. Drug name - INCRUSE ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXO GRP ENGLAND Medicament dispenser Feb, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 62.5MCG BASE/INH POWDER;INHALATION Prescription

59. Drug name - INJECTAFER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754702 AM REGENT Methods and compositions for administration of iron Feb, 2028

(5 years from now)

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Treatment: Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex; method of treating iron deficiency anemia in adults who have intolerance to or have had unsatisfactory response to oral iron associated with heavy uterine bleeding or a gastrointestinal disorder by intravenously administering ferric carboxymaltose; a method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; a method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; method of treating ida in adults & pediatric patients 1 yr & older having intolerance or unsatisfactory response to oral iron associated with heavy uterine bleeding or gastrointestinal disorder by intravenously administering ferric carboxymaltose; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM IRON/20ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
750MG IRON/15ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
100MG IRON/2ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
500MG IRON/10ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription

60. Drug name - INQOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(6 years from now)

CN101827856A OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

CN101827856B OTSUKA 2'-Fluoro--2'-Deoxy-Tetrahydro-Uridine As Cytosine Nucleoside Deaminase Inhibitor
Oct, 2028

(6 years from now)

IN201003209P1 OTSUKA 2 '-Fluoro-2 ' -Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

IN286739B OTSUKA 2'-Flu0R0-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2447272A1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2447272B1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2207786A1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2207786B1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods Oct, 2028

(6 years from now)

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; method for inhibiting degradation of a cda substrate by administering cedazuridine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG;35MG TABLET;ORAL Prescription

61. Drug name - INREBIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199 IMPACT Use of bi-aryl meta-pyrimidine inhibitors of kinases Jun, 2028

(5 years from now)

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription

62. Drug name - INTRAROSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629129 MILLICENT Pharmaceutical compositions Aug, 2028

(5 years from now)

US8957054 MILLICENT Pharmaceutical compositions Aug, 2028

(5 years from now)

Drugs and Companies using PRASTERONE ingredient

Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Dosage: INSERT;VAGINAL

More Information on Dosage
Strength Dosage Availability
6.5MG INSERT;VAGINAL Prescription

63. Drug name - JAKAFI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN103524509A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN103524509B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731B1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369A1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752B2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752B1 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731A1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752A2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369B1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016429 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

US8829013 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); For the treatment of polycythemia vera; for the treatment of intermediate or high-risk myelofibrosis; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; For treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

64. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8414921 MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin Jul, 2028

(5 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

65. Drug name - JARDIANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription

66. Drug name - JUBLIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512640 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US11213519 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US10828369 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US9566272 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US9877955 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Antimycotic uses, specifically treatment of onychomycosis; topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
10% SOLUTION;TOPICAL Prescription

67. Drug name - KAZANO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

EP1586571B1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571A1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571B3 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;1GM TABLET;ORAL Prescription
EQ 12.5MG BASE;500MG TABLET;ORAL Prescription

68. Drug name - KEPPRA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858122 UCB INC Extended release formulation of levetiracetam Sep, 2028

(5 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
500MG TABLET, EXTENDED RELEASE;ORAL Prescription
750MG TABLET, EXTENDED RELEASE;ORAL Prescription

69. Drug name - KISQALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

70. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;EQ 200MG BASE TABLET;ORAL Prescription

71. Drug name - KORLYM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921348 CORCEPT THERAP Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists Aug, 2028

(5 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

72. Drug name - KYBELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8242294 KYTHERA BIOPHARMS Synthetic bile acid compositions and methods
May, 2028

(5 years from now)

CN106083969B KYTHERA BIOPHARMS Synthetic Bile Acid Composition, Method And Preparation
Jun, 2028

(5 years from now)

CN106083969A KYTHERA BIOPHARMS Synthetic Bile Acid Composition, Method And Preparation
Jun, 2028

(5 years from now)

CN108191940B KYTHERA BIOPHARMS Synthetic Bile Acid Compositions, Methods And Formulations
Jun, 2028

(5 years from now)

CN108191940A KYTHERA BIOPHARMS Synthetic Bile Acid Composition, Method And Preparation
Jun, 2028

(5 years from now)

EP3002290A3 KYTHERA BIOPHARMS Synthesis Of Deoxycholic Acid (Dca)
Jun, 2028

(5 years from now)

EP2407475B1 KYTHERA BIOPHARMS Synthetic Bile Acid Preparation
Jun, 2028

(5 years from now)

EP2407475A3 KYTHERA BIOPHARMS Synthetic Bile Acid Composition, Method, And Preparation
Jun, 2028

(5 years from now)

EP3002290A2 KYTHERA BIOPHARMS Synthesis Of Deoxycholic Acid (Dca)
Jun, 2028

(5 years from now)

EP3002290B1 KYTHERA BIOPHARMS Synthesis Of Deoxycholic Acid (Dca)
Jun, 2028

(5 years from now)

EP2407475A2 KYTHERA BIOPHARMS Synthetic Bile Acid Preparation
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461140 KYTHERA BIOPHARMS Synthetic bile acid compositions and methods Feb, 2028

(5 years from now)

US9949986 KYTHERA BIOPHARMS Synthetic bile acid compositions and methods Feb, 2028

(5 years from now)

US9522155 KYTHERA BIOPHARMS Synthetic bile acid compositions and methods Feb, 2028

(5 years from now)

US8546367 KYTHERA BIOPHARMS Synthetic bile acid compositions and methods Feb, 2028

(5 years from now)

US9636349 KYTHERA BIOPHARMS Synthetic bile acid compositions and methods Feb, 2028

(5 years from now)

US8883770 KYTHERA BIOPHARMS Synthetic bile acid compositions and methods Feb, 2028

(5 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Treatment: Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as described in the approved labeling; Method for reduction of submental fat

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
20MG/2ML (10MG/ML) SOLUTION;SUBCUTANEOUS Prescription

73. Drug name - LAMICTAL ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339504 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine Jul, 2028

(5 years from now)

US8840925 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine Jul, 2028

(5 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
50MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
100MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
200MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription

74. Drug name - LAMICTAL XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637512 GLAXOSMITHKLINE LLC Formulations and method of treatment Jun, 2028

(5 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription
100MG TABLET, EXTENDED RELEASE;ORAL Prescription
200MG TABLET, EXTENDED RELEASE;ORAL Prescription
250MG TABLET, EXTENDED RELEASE;ORAL Prescription
300MG TABLET, EXTENDED RELEASE;ORAL Prescription

75. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

EP2231195B1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077A1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 NOVARTIS Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077B1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194B1 NOVARTIS Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231195A2 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

76. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265900 SUNOVION RESP Disposable ampoule for an aerosol generating device Dec, 2028

(6 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

77. Drug name - LOSEASONIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration Dec, 2028

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.02MG,0.1MG;0.01MG,N/A TABLET;ORAL Prescription

78. Drug name - LYNPARZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8247416 ASTRAZENECA Phthalazinone derivative
Sep, 2028

(5 years from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued

79. Drug name - MINIVELLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9724310 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730900 NOVEN Transdermal estrogen device and delivery Jul, 2028

(5 years from now)

US9833419 NOVEN Transdermal estrogen device and delivery Jul, 2028

(5 years from now)

Drugs and Companies using ESTRADIOL ingredient

Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
0.025MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.0375MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.05MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.075MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

80. Drug name - MIRAPEX ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7695734 BOEHRINGER INGELHEIM Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof Apr, 2028

(5 years from now)

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
0.375MG TABLET, EXTENDED RELEASE;ORAL Prescription
0.75MG TABLET, EXTENDED RELEASE;ORAL Prescription
1.5MG TABLET, EXTENDED RELEASE;ORAL Prescription
2.25MG TABLET, EXTENDED RELEASE;ORAL Prescription
3MG TABLET, EXTENDED RELEASE;ORAL Prescription
3.75MG TABLET, EXTENDED RELEASE;ORAL Prescription
4.5MG TABLET, EXTENDED RELEASE;ORAL Prescription

81. Drug name - MITOSOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9539241 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jan, 2028

(5 years from now)

Drugs and Companies using MITOMYCIN ingredient

Treatment: NA

Dosage: FOR SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.2MG/VIAL FOR SOLUTION;TOPICAL Prescription

82. Drug name - MORPHABOND ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314788 DAIICHI SANKYO INC Pharmaceutical compositions configured to deter dosage form splitting Aug, 2028

(5 years from now)

US7955619 DAIICHI SANKYO INC Abuse resistant drugs, method of use and method of making Aug, 2028

(5 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
60MG TABLET, EXTENDED RELEASE;ORAL Discontinued
100MG TABLET, EXTENDED RELEASE;ORAL Discontinued

83. Drug name - MOVANTIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7786133 REDHILL Chemically modified small molecules
Sep, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

84. Drug name - MULPLETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8889722 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jul, 2028

(5 years from now)

CN101809008B SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

CN101809008A SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103450110B SHIONOGI INC Pharmaceutical Composition Containing An Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103396313A SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103450110A SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103396313B SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

EP2184279A4 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

EP2184279A1 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

EP2184279B1 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

85. Drug name - MYRBETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8772315 APGDI Pharmaceutical composition for treating overactive bladder Oct, 2028

(6 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: Use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription

86. Drug name - NATAZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8153616 BAYER HLTHCARE Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same Jan, 2028

(5 years from now)

Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient

Treatment: Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A TABLET;ORAL Prescription

87. Drug name - NAYZILAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809322 UCB INC Methods and compositions for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

US8217033 UCB INC Methods and compositions for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

US9687495 UCB INC Methods and systems for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

US9289432 UCB INC Methods and compositions for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

Drugs and Companies using MIDAZOLAM ingredient

Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
5MG/SPRAY SPRAY;NASAL Prescription

88. Drug name - NERLYNX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9630946 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Oct, 2028

(6 years from now)

US10035788 PUMA BIOTECH Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Oct, 2028

(6 years from now)

US9139558 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Oct, 2028

(6 years from now)

Drugs and Companies using NERATINIB MALEATE ingredient

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting; extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

89. Drug name - NESINA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

EP1586571B1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571A1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571B3 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 6.25MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

90. Drug name - NEXAVAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9737488 BAYER HLTHCARE Pharmaceutical composition for the treatment of cancer Sep, 2028

(5 years from now)

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Treatment: Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; treatment of advanced renal cell carcinoma; treatment of unresectable hepatocellular carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

91. Drug name - NICORETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323683 GLAXOSMITHKLINE Flavoring of drug-containing chewing gums Apr, 2028

(5 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Treatment: NA

Dosage: GUM, CHEWING;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE GUM, CHEWING;BUCCAL Over the counter

92. Drug name - NUCYNTA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8536130 COLLEGIUM PHARM INC Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain Sep, 2028

(5 years from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: Management of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 250MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

93. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7732615 ACADIA PHARMS INC N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 17MG BASE TABLET;ORAL Discontinued

94. Drug name - NUVESSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877792 CHEMO RESEARCH SL Compositions for increasing solubility of azole drug compounds that are poorly soluble in water Feb, 2028

(5 years from now)

US7893097 CHEMO RESEARCH SL Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water Feb, 2028

(5 years from now)

US8658678 CHEMO RESEARCH SL Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water Jun, 2028

(5 years from now)

Drugs and Companies using METRONIDAZOLE ingredient

Treatment: Treatment of bacterial vaginosis

Dosage: GEL;VAGINAL

More Information on Dosage
Strength Dosage Availability
1.3% GEL;VAGINAL Prescription

95. Drug name - OFIRMEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383834 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Nov, 2028

(6 years from now)

US9610265 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Nov, 2028

(6 years from now)

US9987238 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Nov, 2028

(6 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: Modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain; Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

96. Drug name - OLUX E

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8460641 MYLAN Microemulsion process and composition Nov, 2028

(6 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Treatment: Treatment of corticosteroid-responsive dermatoses

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% AEROSOL, FOAM;TOPICAL Prescription

97. Drug name - OMNARIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases Feb, 2028

(5 years from now)

Drugs and Companies using CICLESONIDE ingredient

Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults and adolescents 12 years of age and older

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.05MG/SPRAY SPRAY, METERED;NASAL Prescription

98. Drug name - ONGLYZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7951400 ASTRAZENECA AB Coated tablet formulation and method Nov, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription

99. Drug name - ONIVYDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8147867 IPSEN INC Liposomes useful for drug delivery
Aug, 2028

(5 years from now)

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) INJECTABLE, LIPOSOMAL;INTRAVENOUS Prescription

100. Drug name - ONMEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486456 SEBELA IRELAND LTD Itraconazole compositions with improved bioavailability Oct, 2028

(5 years from now)

Drugs and Companies using ITRACONAZOLE ingredient

Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Discontinued

101. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8875704 CURRAX Nasal administration Apr, 2028

(5 years from now)

US10722667 CURRAX Nasal administration Dec, 2028

(6 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method of drug delivery via the nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

102. Drug name - OPSUMIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8367685 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Oct, 2028

(5 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

103. Drug name - OPZELURA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN103524509A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN103524509B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731B1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369A1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752B2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752B1 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731A1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752A2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369B1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610530 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 1.5% BASE CREAM;TOPICAL Prescription

104. Drug name - ORENITRAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(6 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(6 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(6 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.125MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

105. Drug name - ORKAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10597384 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
Dec, 2028

(6 years from now)

CN103626744A VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN103626744B VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN101910156B VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN101910156A VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP2225230B1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP2225230A1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP3170818B1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP3170818A1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653103 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Dec, 2028

(6 years from now)

US9150552 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Dec, 2028

(6 years from now)

US11052075 VERTEX PHARMS INC Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Dec, 2028

(6 years from now)

US8846718 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Dec, 2028

(6 years from now)

US10076513 VERTEX PHARMS INC Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Dec, 2028

(6 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and form i lumacaftor; Treatment of cystic fibrosis in patients 6 years and older who are homozygous for the f508del mutation in the cftr gene using the tablet according to claim 1 of u.s. patent no. 11,052,075, where the tablet further comprises ivacaftor; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor form i and ivacaftor; Treatment of cystic fibrosis in a patient age 12 years or older who is homozygous for the f508del mutation in the cftr gene using the tablet comprising lumacaftor as recited in claim 1, 19, or 21 of u.s. patent no. 10,076,513 and ivacaftor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
125MG;100MG TABLET;ORAL Prescription
125MG;200MG TABLET;ORAL Prescription

106. Drug name - OSENI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

EP1586571B1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571A1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571B3 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 45MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 45MG BASE TABLET;ORAL Prescription

107. Drug name - OSMOLEX ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8389578 ADAMAS PHARMA Composition and method for treating neurological disease Jan, 2028

(5 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 129MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 161MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 193MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 258MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

108. Drug name - OSMOPREP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7687075 SALIX PHARMS Colonic purgative composition with soluble binding agent
Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
0.398GM;1.102GM TABLET;ORAL Prescription

109. Drug name - OSPHENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642079 DUCHESNAY Solid formulations of ospemifene Jul, 2028

(5 years from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

110. Drug name - OTEZLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7427638 AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Feb, 2028

(5 years from now)

Drugs and Companies using APREMILAST ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

111. Drug name - OXLUMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) SOLUTION;SUBCUTANEOUS Prescription

112. Drug name - PENNSAID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252838 HORIZON Diclofenac topical formulation Apr, 2028

(5 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Use of topical diclofenac on a joint for treating osteoarthritis

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% SOLUTION;TOPICAL Prescription

113. Drug name - PERSERIS KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186413 INDIVIOR INC Sustained delivery formulations of risperidone compounds Feb, 2028

(5 years from now)

US9180197 INDIVIOR INC Sustained delivery formulations of risperidone compounds Feb, 2028

(5 years from now)

US10376590 INDIVIOR INC Sustained delivery formulations of risperidone compound Feb, 2028

(5 years from now)

US11013809 INDIVIOR INC Sustained delivery formulations of risperidone compound Feb, 2028

(5 years from now)

US10010612 INDIVIOR INC Sustained delivery formulations of risperidone compounds Feb, 2028

(5 years from now)

Drugs and Companies using RISPERIDONE ingredient

Treatment: Treatment of schizophrenia; Method of treating schizophrenia; Treating schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
90MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription
120MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

114. Drug name - PRADAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7866474

(Pediatric)

BOEHRINGER INGELHEIM Film container Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE CAPSULE;ORAL Prescription
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

115. Drug name - PREPOPIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450338 FERRING PHARMS INC Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof Oct, 2028

(6 years from now)

US8481083 FERRING PHARMS INC Granular compositions of magnesium oxide and citric acid and uses thereof Oct, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
12GM/PACKET;3.5GM/PACKET;10MG/PACKET FOR SOLUTION;ORAL Discontinued

116. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8651103 TEVA BRANDED PHARM Dry powder inhalation apparatus Mar, 2028

(5 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

117. Drug name - PROAIR HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8132712 TEVA BRANDED PHARM Metered-dose inhaler Sep, 2028

(5 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH AEROSOL, METERED;INHALATION Prescription

118. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026284

(Pediatric)

HORIZON PHARMA USA Enterically coated cystamine, cysteamine and derivatives thereof Mar, 2028

(5 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: NA

Dosage: GRANULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription
EQ 300MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription

119. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026284

(Pediatric)

HORIZON Enterically coated cystamine, cysteamine and derivatives thereof Mar, 2028

(5 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

120. Drug name - PROMACTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071129

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8062665

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8052993

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8052994

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8828430

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID TABLET;ORAL Prescription
EQ 25MG ACID TABLET;ORAL Prescription
EQ 50MG ACID TABLET;ORAL Prescription
EQ 75MG ACID TABLET;ORAL Prescription
EQ 100MG ACID TABLET;ORAL Discontinued

121. Drug name - QBREXZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052267 JOURNEY Topical glycopyrrolate formulations Oct, 2028

(6 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 2.4% BASE CLOTH;TOPICAL Prescription

122. Drug name - QSYMIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895057 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity Jun, 2028

(5 years from now)

US9011906 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity Jun, 2028

(5 years from now)

US9011905 VIVUS Low dose topiramate/phentermine composition and methods of use thereof Jun, 2028

(5 years from now)

US8895058 VIVUS Low dose topiramate/phentermine composition and methods of use thereof Jun, 2028

(5 years from now)

Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient

Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 3.75MG BASE;23MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 7.5MG BASE;46MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 11.25MG BASE;69MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 15MG BASE;92MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

123. Drug name - QTERN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

Treatment: Treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 5MG BASE TABLET;ORAL Prescription
10MG;EQ 5MG BASE TABLET;ORAL Prescription

124. Drug name - QTERNMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

125. Drug name - QUTENZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9226903 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer Dec, 2028

(6 years from now)

Drugs and Companies using CAPSAICIN ingredient

Treatment: NA

Dosage: PATCH;TOPICAL

More Information on Dosage
Strength Dosage Availability
8% PATCH;TOPICAL Prescription

126. Drug name - QVAR REDIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8132712 NORTON WATERFORD Metered-dose inhaler Sep, 2028

(5 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.04MG/INH AEROSOL, METERED;INHALATION Prescription
0.08MG/INH AEROSOL, METERED;INHALATION Prescription

127. Drug name - RAYALDEE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778373 EIRGEN Methods for controlled release oral dosage of a vitamin D compound Apr, 2028

(5 years from now)

US9498486 EIRGEN Method for controlled release oral dosage of a vitamin D compound Apr, 2028

(5 years from now)

US9925147 EIRGEN Method for treating secondary hyperparathyroidism in CKD Apr, 2028

(5 years from now)

US11154509 EIRGEN Methods for controlled release oral dosage of a vitamin D compound Apr, 2028

(5 years from now)

US9408858 EIRGEN Method for treating secondary hyperparathyroidism in CKD Apr, 2028

(5 years from now)

US8207149 EIRGEN Method for treating secondary hyperparathyroidism in CKD Apr, 2028

(5 years from now)

US8361488 EIRGEN Methods and compositions for controlled release oral dosage of a vitamin D compound Jul, 2028

(5 years from now)

US8426391 EIRGEN Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Aug, 2028

(5 years from now)

Drugs and Companies using CALCIFEDIOL ingredient

Treatment: Administration of 25-hydroxyvitamin d3 by controlled release; Use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4; Treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and cmax24hr/c24hr is reduced compared to bolus iv injection and immediate-release, oral dosing; treating secondary hyperparathyroidism in chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level and the sustained release is over at least 10 hours; treating secondary hyperparathyroidism in chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level and cmax is reduced compared to bolus iv injection and immediate-release, oral dosing; treating shpt in ckd with sustained release calcifediol to reduce serum parathyroid hormone level and change in serum concentration of calcifediol in dose interval is reduced compared to bolus iv injection and immediate-release, oral dosing; treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and tmax is increased compared to bolus iv injection and immediate-release, oral dosing; Treating secondary hyperparathyroidism in stage 3/4 chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversuppression; Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease; Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d; Use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
0.03MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

128. Drug name - RAYOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168218 HORIZON Delayed release tablet with defined core geometry Jan, 2028

(5 years from now)

Drugs and Companies using PREDNISONE ingredient

Treatment: Treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET, DELAYED RELEASE;ORAL Prescription
2MG TABLET, DELAYED RELEASE;ORAL Prescription
5MG TABLET, DELAYED RELEASE;ORAL Prescription

129. Drug name - RECLAST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates Feb, 2028

(5 years from now)

US7932241

(Pediatric)

NOVARTIS Pharmaceutical products comprising bisphosphonates Aug, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE/100ML INJECTABLE;INTRAVENOUS Prescription

130. Drug name - REMODULIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(6 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(6 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(6 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Sep, 2028

(5 years from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Sep, 2028

(5 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Treatment: Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
2.5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
10MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
20MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription

131. Drug name - REVLIMID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741929 CELGENE Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas Mar, 2028

(5 years from now)

Drugs and Companies using LENALIDOMIDE ingredient

Treatment: Use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG CAPSULE;ORAL Prescription
5MG CAPSULE;ORAL Prescription
10MG CAPSULE;ORAL Prescription
15MG CAPSULE;ORAL Prescription
20MG CAPSULE;ORAL Prescription
25MG CAPSULE;ORAL Prescription

132. Drug name - REXULTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48059 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Dec, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
0.25MG TABLET;ORAL Prescription
0.5MG TABLET;ORAL Prescription
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription

133. Drug name - RHOFADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7812049 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists May, 2028

(5 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

134. Drug name - ROXYBOND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7955619 PROTEGA PHARMS Abuse resistant drugs, method of use and method of making Aug, 2028

(5 years from now)

US10314788 PROTEGA PHARMS Pharmaceutical compositions configured to deter dosage form splitting Aug, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Discontinued
15MG TABLET;ORAL Discontinued
30MG TABLET;ORAL Discontinued

135. Drug name - ROZLYTREK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

CN103923072A GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN101754956B GENENTECH INC Substituted Indazole Derivatives Having Activity Of Kinase Inhibitors
Jul, 2028

(5 years from now)

CN101754956A GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN103923072B GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

IN201000870P4 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

IN281852B GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

EP2176231B1 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

EP2176231A1 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription
200MG CAPSULE;ORAL Prescription

136. Drug name - RYTARY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377474 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US8454998 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9533046 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US8557283 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9089608 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9901640 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9089607 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9463246 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Treatment: Treatment of parkinson's disease; treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of post-encephalitic parkinsonism; treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of parkinson's disease; treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; method of providing a therapeutically effective and stable median blood plasma level of levodopa

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
23.75MG;95MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
36.25MG;145MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
48.75MG;195MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
61.25MG;245MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

137. Drug name - SAVAYSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149532 DAIICHI SANKYO INC Pharmaceutical composition Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

138. Drug name - SAXENDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism Mar, 2028

(5 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

139. Drug name - SEASONIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration Dec, 2028

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.03MG,0.01MG;0.15MG,N/A TABLET;ORAL Prescription

140. Drug name - SEEBRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device Oct, 2028

(6 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation Oct, 2028

(6 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
15.6MCG/INH POWDER;INHALATION Discontinued

141. Drug name - SEYSARA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9481639 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders Aug, 2028

(5 years from now)

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 60MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

142. Drug name - SIGNIFOR LAR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9351923 RECORDATI RARE Extended-release composition comprising a somatostatin derivative in microparticles May, 2028

(5 years from now)

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 20MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 30MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 40MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 60MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription

143. Drug name - SILENOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234954 CURRAX Low-dose doxepin for treatment of sleep disorders in elderly patients Jan, 2028

(5 years from now)

US10548871 CURRAX Low-dose doxepin formulations and methods of making and using the same Apr, 2028

(5 years from now)

US11096920 CURRAX Low-dose doxepin formulations and methods of making and using the same Apr, 2028

(5 years from now)

US9907780 CURRAX Low-dose doxepin formulations and methods of making and using the same Apr, 2028

(5 years from now)

US9107898 CURRAX Methods of using low-dose doxepin for the improvement of sleep May, 2028

(5 years from now)

Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 3MG BASE TABLET;ORAL Prescription
EQ 6MG BASE TABLET;ORAL Prescription

144. Drug name - SIVEXTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(5 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

145. Drug name - SORILUX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263580 MAYNE PHARMA Vitamin formulation May, 2028

(5 years from now)

Drugs and Companies using CALCIPOTRIENE ingredient

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.005% AEROSOL, FOAM;TOPICAL Prescription

146. Drug name - SOVALDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

EP2826784A1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2826784B1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334270

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

Drugs and Companies using SOFOSBUVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription

147. Drug name - SPIRIVA RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component Sep, 2028

(5 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.00125MG BASE/INH SPRAY, METERED;INHALATION Prescription
EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

148. Drug name - SPY AGENT GREEN KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8185176 NOVADAQ TECH Method and apparatus for vasculature visualization with applications in neurosurgery and neurology Jun, 2028

(5 years from now)

Drugs and Companies using INDOCYANINE GREEN ingredient

Treatment: Visualization of vessels, blood flow and tissue perfusion of vessel with arteriovenous malformation in vascular, gastrointestinal, organ transplant, and plastic, micro- and reconstructive, including minimally invasive, surgery

Dosage: POWDER;INTRAVENOUS, INTERSTITIAL

More Information on Dosage
Strength Dosage Availability
25MG/VIAL POWDER;INTRAVENOUS, INTERSTITIAL Prescription

149. Drug name - STAXYN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613950 BAYER HLTHCARE Pharmaceutical forms with improved pharmacokinetic properties Dec, 2028

(6 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription

150. Drug name - STIOLTO RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component Sep, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

151. Drug name - STRIVERDI RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

152. Drug name - SUPRAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233112 LUPIN LTD Pharmaceutical compositions of cefixime Dec, 2028

(6 years from now)

Drugs and Companies using CEFIXIME ingredient

Treatment: Methods for treating bacterial infections

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
500MG/5ML FOR SUSPENSION;ORAL Prescription

153. Drug name - SYMBICORT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8528545 ASTRAZENECA Inhaler device that reduces the risk for miscounting a dosage Oct, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
0.08MG/INH;0.0045MG/INH AEROSOL, METERED;INHALATION Prescription
0.16MG/INH;0.0045MG/INH AEROSOL, METERED;INHALATION Prescription

154. Drug name - SYMPROIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46365